SERA - NASDAQ

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%

HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$85.74M

EPS-0.6700

P/E Ratio-3.35

Earnings Date08/05/2026

sera

Net Debt

Last Annual Value

-1.60M

3-Year CAGR

61%

5-Year CAGR

20%

10-Year CAGR

18%

Adjust for Inflation

Sera Prognostics, Inc. Competitors Analysis of Net Debt

SERA · NASDAQ

Company	Net Debt	CAGR 3Y	CAGR 5Y	CAGR 10Y
Sera Prognostics, Inc. NASDAQ:SERA	-1.60M	N/A	N/A	N/A
Rapid Micro Biosystems, Inc. NASDAQ:RPID	3.84M	N/A	N/A	N/A
Apyx Medical Corporation NASDAQ:APYX	7.60M	N/A	N/A	N/A
Context Therapeutics Inc. NASDAQ:CNTX	-65.88M	N/A	N/A	N/A
DocGo Inc. NASDAQ:DCGO	-21.84M	N/A	N/A	N/A
Ovid Therapeutics Inc. NASDAQ:OVID	266.00K	N/A	N/A	N/A
Insight Molecular Diagnostics Inc. NASDAQ:IMDX	-8.09M	N/A	N/A	N/A
VistaGen Therapeutics, Inc. NASDAQ:VTGN	-65.62M	N/A	N/A	N/A
Armata Pharmaceuticals, Inc. AMEX:ARMP	279.33M	37.8%	58.8%	N/A
Lucid Diagnostics Inc. NASDAQ:LUCD	-8.88B	N/A	N/A	N/A
TuHURA Biosciences, Inc. NASDAQ:HURA	-3.12M	N/A	N/A	N/A

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

HIDDEN

Intrinsic Value

Current Price: $2.245

Related Guides

Blog Categories

Continue your SERA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.